Konica Minolta Partners with Dealers to Give Back
July 08, 2021 09:12 ET | Konica Minolta Business Solutions U.S.A., Inc.
Ramsey, NJ, July 08, 2021 (GLOBE NEWSWIRE) -- Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) is proud to announce a collaboration with its dealer partners to celebrate wins and pay...
Vaccinex logo
Vaccinex Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer’s Disease and in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
June 08, 2021 07:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease...
Vaccinex logo
Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 17, 2021 08:15 ET | Vaccinex, Inc.
Initiated Phase 2 study of pepinemab in combination with KEYTRUDA® in advanced, recurrent or metastatic head and neck cancer Announced publication of results from CLASSICAL-Lung phase 1b/2 clinical...
Vaccinex logo
Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable
October 26, 2020 07:55 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex logo
Vaccinex Delivers Virtual Presentation at the Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD™ Focus Meeting 2020
April 07, 2020 07:55 ET | Vaccinex, Inc.
ROCHESTER, N.Y., April 07, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex logo
Vaccinex Announces $3 Million Award from the Alzheimer’s Drug Discovery Foundation
December 10, 2019 08:02 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and cancer,...
Vaccinex logo
Vaccinex Details Scientific Rationale for Expanding Pepinemab Clinical Programs to Include Alzheimer’s Disease
December 09, 2019 07:55 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex logo
Vaccinex Announces Award Notice from the Alzheimer’s Association 2020 Part the Cloud Program
November 14, 2019 07:55 ET | Vaccinex, Inc.
Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington’s disease, will be tested for similar effects in Alzheimer’s disease ...
USF Researcher Develops Therapeutic Vaccine to Combat Alzheimer’s Disease and Neurodegenerative Disorders
January 30, 2017 06:00 ET | Alzamend Neuro, Inc.
SALT LAKE CITY, Jan. 30, 2017 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) reprints by permission of the University of South Florida (USF) Technology Transfer Office this...
Better Hearing Institute logo
Link to memory, cognitive function elevates urgency of treating hearing loss
September 16, 2016 16:11 ET | Better Hearing Institute
WASHINGTON, Sept. 16, 2016 (GLOBE NEWSWIRE) -- A growing body of research links untreated hearing loss to impaired memory and diminished cognitive function, raising the significance of hearing health...